The current study aimed to develop and new, simple, accurate, economical and stability-indicating RP-HPLC for simultaneous estimation of Amlodipine Besylate, Valsartan and its related substances in their film-coated tablets dosage form. Chromatographic system was performed on the YMC ODS-A C18 (150 mm × 4.6 mm, 5μm particle size) using a binary gradient elution consist of two solvent systems, solution (A) 0.02 monobasic sodium phosphate Adjust with phosphoric acid to a pH of 2.5 and solution (B) consisting of Solution A: Acetonitrile (45:55). At a flow rate of 1.0 mL/min, injection volume 10 µL, UV detection at 235 nm, column oven temperature 30 ○ C and autosampler temperature 10 ○ C. This method was validated according to ICH requirements for new methods, which include accuracy, precision, selectivity, robustness, ruggedness, LOD, LOQ, linearity and range. Linear relationships were obtained in the ranges of 10-300 µg/mL and 5-200 µg/mL with correlation coefficients of 0.9997 and 0.9998 for Amlodipine Besylate and Valsartan respectively. The forced degradation studies as acidity, alkalinity, oxidation, heat, thermal, humidity and photodegradation were performed according to ICH guidelines.
Introduction
Amlodipine (AML) is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that AML binds to both dihydropyridine and no dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. AML inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells AML is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure AML has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This (Prinzmetal's or variant) angina [1] . AML besylate is the besylate salt of AML, a long-acting calcium channel blocker. AML besylate ( Figure   1a ) is chemically described as 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridine dicarboxylate, mono benzene sulphonate. Its empirical formula is C20H25CIN2O5•C6H6O3S, AML besylate is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. [2] . Valsartan (VAL), (Figure 1b VAL is white or almost white, hygroscopic powder, practically insoluble in water, freely soluble in anhydrous ethanol, sparingly soluble in methylene chloride [2] . AML and VAL are official in BP and USP [2, 3] . Literature review showed that few analytical methods have been described for the estimation of AML and VAL including spectrophotometric [4] [5] [6] [7] , highperformance liquid chromatography (HPLC) [8] [9] [10] [11] [12] [13] [14] , spectrofluorimetric method [15] [16] [17] , electrochemical and voltammetric methods [18] [19] [20] [21] [22] had been reported for the estimation of AML and VAL in pure or in dosage forms. According to the best of my knowledge, there is no Stability indicating new-RP-HPLC method for simultaneous determination of Amlodipine Besylate, Valsartan and its related substances in their film-coated tablets dosage form. The current study was designed to develop and validate a simple, sensitive, and accurate stability indicating RP-HPLC method for the analysis of amlodipine besylate and valsartan and its related substances in Alkapress Plus F.C.T. label claims (5/80 mg) and (5/160 mg) and (10/160 mg) (Amlodipine Besylate/Valsartan) tablet. Validation will be conducted in accordance with the International Conference of Harmonization guidelines (ICH Q2) [23] . 
Experimental

Materials and methods
Mobile phase preparation
Solution (A) 0.02 (2.4 gm) monobasic sodium phosphate in 1000 ml water adjust with phosphoric acid to a pH of 2.5. And solution (B) consisting of solution A: acetonitrile (45:55).
Diluent preparation
Solution A and solution B (50:50) ( Table  1) .
HPLC Chromatographic Conditions
Chromatographic separation was performed on column YMC-ODS-A (15 cm× 4.6 mm) 5 µm. Using a mobile phase mixture as gradient system at column oven temperature 30 °C, flow rate of 1.0 mL/min, Sample cooler temperature 10 °C and UV detection was performed at 235 nm, injection volume was 10 μL and run time was 24 min. 
Preparation of Standard Solution
Sample Solution Preparation
For ( 
For (10/160) Concentration
Sample stock solution: weigh 10 tablets of Alkapress plus (10/160) and transfer completely into a 500 mL volumetric flask. Initially add water to 10% of the final volume (about 50 mL) and sonicate to disperse as needed. Add diluent using about 70% of the final volume and shake for up to 45 min to disperse. Following dispersion, sonicate for 15 minutes. And shake for 30 min. Dilute with diluent to volume to obtain a solution containing known nominal concentrations of 0.2 mg/mL of amlodipine and 3.2 mg/mL of valsartan. Centrifuge the solution for about 10 min at 3000 rpm. 
Construction of calibration curves
Different concentration of AML and VAL equivalent to (10-300 µg/mL) and (5-200 µg/mL) respectively. were separately weighted from their respective stock standard into separate series of 100 mL volumetric flasks, and the volumes were made up to volume with diluent. Duplicate 20 µL injections were made for each concentration maintaining the flow rate at 1.0 mL/min and the effluent was UVscanned at 235 nm. 
Results and discussion
Methods development and optimization
Method validation
The method was validated, in accordance with ICH guidelines (ICH Q2R1), for system suitability, precision, accuracy, linearity, specificity, ruggedness, robustness, LOD, and LOQ [23] . Table 2 .
Limit of detection and quantitation
These approaches are based on the standard deviation of the response and the Slope. A specific calibration curve should be studied using samples, containing an analyte in the range of LOD and LOQ. The residual standard deviation of a regression line or the standard deviation of yintercepts of regression lines may be used as the standard deviation. LOD=3.3×σ /slope and LOQ =10×σ /slope, where σ= the standard deviation of the response Table1.
Accuracy and recovery
Accuracy expresses the closeness of agreement between the value found and the value that is accepted as either a conventional true value or an accepted reference value. Accuracy of the proposed methods was calculated as the percentage recoveries of pure samples of the studied drugs. Accuracy is assessed using three different concentrations (50.0, 100 and 150 μg/mL) (i.e. three concentrations and three replicates). Concentrations were calculated from the corresponding regression equations. The mean % recoveries for AML and VAL were between 98.0% to 102% and were shown in Table 3 .
Formulation assay
Method precision evaluates the variation experienced by a single analyst on a single instrument. Method precision does not distinguish between variation from the instrument or system alone and from the sample preparation process. Method precision is performed by analyzing multiple replicates of an assay composite sample using the analytical method. The assay is calculated and reported for each value. The results were displayed in Table 4 . 
Intermediate precision (ruggedness)
Intermediate precision refers to variations within a laboratory as with different days, with different instruments, by different analysts, and so forth. Intermediate precision was formally known as ruggedness. A second analyst repeats the method precision analysis on a different day using different conditions and different instruments. The recovery values are calculated and reported. A statistical comparison is made to the first analyst's results in Table 5 .
Robustness
The robustness of the proposed methods was evaluated in the development phase where the effects of different factors on method were studied to obtain the optimum parameters for complete separation. Robustness of the method was studied by deliberately varying parameters like flow rate (±0.1 mL/min) and studying the effect of changing mobile phase pH by (± 0.2), acetonitrile composition (±5%) and column temperature changed (±5 °C). The low values of the %RSD, as given in Table 5 , indicated the robustness of the proposed methods.
System suitability
System suitability testing is an integral part of many analytical procedures. The tests are based on the concept that the equipment, electronics, analytical operations, and samples to be analyzed constitute an integral system that can be evaluated as such. System suitability was checked by calculating tailing factor (T), column efficiency (N), resolution (Rs) factors. All calculated parameters were within the acceptable limits indicating good selectivity of the methods and ensuring system performance, Table 6 . 
Specificity
Placebo interference
Weigh the equivalent to 10 tablets of Alkapress plus placebo and transfer completely into a 500 mL volumetric flask. Initially add water to 10% of the final Volume (about 50 mL) and sonicate to disperse as needed. Add diluent using about 70% of the final volume and shake for up to 45 min to disperse. Following dispersion, Sonicate for 15 minutes. And shake for 30 min. Dilute with diluent to volume and mix well. Centrifuge the solution for about 10 min at 3000 rpm. Filter using 0.2 µm PTFE syringe membrane filter. The obtained results confirmed that the APIs do not interfere with the placebo and diluent.
Forced degradation
Forced degradation studies are undertaken to degrade the sample (drug product and placebo) deliberately. These studies are used to evaluate an analytical method ability to measure an active ingredient and its degradation products without interference. Samples or drug product and drug substance are exposed to heat, light, acid, base, and oxidizing agent to produce 10%-30% degradation of the active whenever possible. The degraded samples are then analyzed using the method to determine if there are interferences with the related substances. The results were summarized in Table 7 .
Acid degradation
Weigh accurately about 350 mg and 400 mg of AML and VAL. Transfer completely into a 250 mL volumetric flask, add methanol to 5% of the final volume to dissolve (about 12.5 mL), and add diluent to about 70% of the final volume, sonicate for about 10 minutes, complete up to volume using diluent and mix well.
Base degradation
Peroxide degradation
Weigh accurately about 350 mg and 400 mg of AML and VAL. Transfer completely into a 250 mL volumetric flask, add methanol to 5% of the final volume to dissolve (about 12.5 mL), and add diluent to about 70% of the final volume, sonicate for about 10 minutes, complete up to volume using iluent and mix well.
Thermal degradation
Transfer 10 mL of Standard Stock Solution, heat for 1 hrs at 85 °C, Complete to 100 mL volumetric flask with diluents. Add 50 mL diluent.
Accelerated stability study
Accelerated stability studies were performed at storage condition 40±2 OC & relative humidity 75±5% for 6 months. Accelerated stability studies intended to increase the rate of physical change or chemical degradation by using extravagant conditions of elevated temperature and humidity. The obtained results in Table 8 showed that no degradation was occurred during this intervals as shown in (Figure 3 ). 
Conclusion
The main objective of this work is to develop accurate, simple, precise, specific, and rapid RP-HPLC method for simultaneous estimation of the analysis of Amlodipine Besylate and Valsartan and its related substances in Alkapress Plus F.C.T. label claims (5/80 mg) and (5/160 mg) and (10/160 mg) (Amlodipine Besylate/ Valsartan) tablet. The results of stress testing that have been undertaken according to the International Conference on Harmonization (ICH) guidelines. Based on the above results, the analytical method is valid, fit for use and can be used for quality control and stability study.
